ELEVAI Labs Unveils New Paradigm-Shifting Skincare Procedure to the American Society for Laser Medicine and Surgery (ASLMS)

ELEVAI Labs is Set to Launch its New Groundbreaking Approach to Pre- and Post-Procedure Skincare

ELEVAI Labs, a science-based, data-driven aesthetic skincare company, will launch its revolutionary core technology platform, PREx™ (Precision Regenerative Exosome Technology™), at The American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Phoenix on April 13th.

Co-Founded by Dr. Jordan Plews, a Stanford-trained scientist with a background in biochemical engineering and stem cell research, ELEVAI’s trailblazing aesthetics applications are revolutionizing pre- and post-procedure skincare. PREx™, ELEVAI’s proprietary technology platform, harnesses the power of exosomes—nanoparticle compartments packed with growth factors, to optimize the appearance of skin and improve the patient experience. All ELEVAI science-backed formulations feature ELEVAI Exosomes™ as the primary ingredient that mimics the elegant biological factors of nature involved in repair and recovery, which supports the skin’s natural healing process.

During ASLMS, ELEVAI will lead the conversation around topical exosomes and their transformative approach to pre- and post-procedural skincare. Dr. Jordan Plews and Dr. Natalie Curcio will unveil PREx™ and its ability to transform the skincare industry while presenting new data quantifying the appearance of the reduction of redness and pigmentation in subjects’ skin at week eight and week twelve of daily topical application of ELEVAI products, obtained through the Canfield Reveal Imaging System.

WealthyVC.com Kicks Off Coverage of the Emerging and Recession Resilient Cosmeceuticals Industry

Commenting on the announcement, ELEVAI Labs CEO Dr. Jordan Plews stated:

“Behind everything we do is the desire to provide innovative, safe, high-quality, and efficacious formulations. We are excited to unveil PREx™ at the ASLMS Meeting and share our transformative approach to topical exosome skincare. New data suggests ELEVAI’s proprietary PREx TechnologyTM helps aesthetic providers deliver improved results for patients, contributing towards reduced recovery time and improved outcomes.”

The ELEVAI E-Series™ is the first-to-market topical exosome product series intentionally developed to support skin before and after energy-based procedures to optimize aesthetic outcomes and elevate the patient experience.

Dr. Natalie Curcio also commented on the news, adding:

“This approach to skincare will revolutionize the way patients care for their skin leading up to and following in-office procedures. The ASLMS Meeting provides the perfect platform for ELEVAI to showcase its groundbreaking technology. We look forward to sharing a deeper understanding of the capacity for using exosomes pre-and post-treatment.”

For more information, visit the ELEVAI Skincare website here.

Interested in buying ELEVAI Skincare products? Click here to find an authorized ELEVAI Skincare Professional.

View the original ELEVAI Labs press release here.

Please consider Following Us on Social Media via the Wealthy VC social links below to stay up to date on Elevai Labs.

????Join the Discussion in the Wealthy VC Investor Group

????Have a Stock Tip or New  Story Suggestion? Email us at Invest@WealthyVC.com

Elevai Labs Inc. is a paid client of Wealthy VC.

Wealthy VC’s parent company has been compensated $13,500 per month for 12 months for investor relations, public relations, and market awareness services by Elevai Labs Inc.

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

View Full Disclaimer Here